PANITUMUMAB and DEATH

Overview

DEATH is the #4 most commonly reported adverse reaction for PANITUMUMAB, manufactured by Amgen, Inc. There are 908 FDA adverse event reports linking PANITUMUMAB to DEATH. This represents approximately 2.9% of all 31,648 adverse event reports for this drug.

Patients taking PANITUMUMAB who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

DEATH is a less commonly reported adverse event for PANITUMUMAB, but still significant enough to appear in the safety profile.

Other Side Effects of PANITUMUMAB

In addition to death, the following adverse reactions have been reported for PANITUMUMAB:

• RASH — 1,722 reports
• DIARRHOEA — 1,526 reports
• DERMATITIS ACNEIFORM — 1,005 reports
• NEUTROPENIA — 886 reports
• SKIN TOXICITY — 850 reports
• HYPOMAGNESAEMIA — 793 reports
• NAUSEA — 780 reports
• DISEASE PROGRESSION — 712 reports
• NEUROPATHY PERIPHERAL — 688 reports
• COLORECTAL CANCER METASTATIC — 625 reports

Other Drugs Associated with DEATH

The following drugs have also been linked to death in FDA adverse event reports:

Does PANITUMUMAB cause DEATH?

DEATH has been reported as an adverse event in 908 FDA reports for PANITUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is DEATH with PANITUMUMAB?

DEATH accounts for approximately 2.9% of all adverse event reports for PANITUMUMAB, making it a notable side effect.

What should I do if I experience DEATH while taking PANITUMUMAB?

If you experience death while taking PANITUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages